AbbVie Header AbbVie Header

X

Find the latest Drugs in Development and Pipeline Prospector News of PPD.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
PPD
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
929 North Front Street Wilmington, NC 28401-3331
Telephone
Telephone
+910 251 0081

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

left grey arrow
right gray arrow
  • Development Update

Details:

TH1902 (Docetaxel-TH19P01 Conjugate) is Theratechnologies’ proprietary peptide drug conjugate (“PDC”) linked, a well-established and well-characterized cytotoxic agent.


Lead Product(s): Docetaxel-TH19P01 Conjugate

Therapeutic Area: Oncology Product Name: TH1902

Highest Development Status: Phase IProduct Type: Peptide

Recipient: Theratechnologies

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 14, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

sNDA is supported by Phase 3 Study 1601 for FINTEPLA® (fenfluramine) for treatment of seizures associated with Lennox-Gastaut Syndrome to FDA. FINTEPLA is approved by the FDA and European Commission for treatment of seizures associated with Dravet syndrome.


Lead Product(s): Fenfluramine

Therapeutic Area: Neurology Product Name: Fintepla

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Zogenix

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 28, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

PPD will manage the Phase 1b/2a clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, also known as FW-420.


Lead Product(s): Niclosamide

Therapeutic Area: Gastroenterology Product Name: FW-420

Highest Development Status: IND EnablingProduct Type: Small molecule

Partner/Sponsor/Collaborator: First Wave BioPharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 13, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

PPD will work with U.S. Army Medical Materiel Development Activity’s Warfighter Brain Health Project Management Office to test the efficacy and safety of at least two pharmacotherapeutic drugs for the treatment of PTSD in U.S. military active duty personnel and veterans.


Lead Product(s): Undisclosed

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Undisclosed

Partner/Sponsor/Collaborator: US Army

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 18, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Deals

Details:

Under the terms of the agreement, PPD will manage the Phase 2 clinical trial for an immediate-release capsule formulation of micronized oral niclosamide, also known as FW-1022.


Lead Product(s): Niclosamide

Therapeutic Area: Infections and Infectious Diseases Product Name: FW-1022

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: First Wave BioPharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 09, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY